CG Oncology, Inc.
CGON
$19.28
$1.659.36%
| 12/31/2024 | 09/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | 45,500.00% | 377.78% | 172.68% | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 45,500.00% | 377.78% | 172.68% | -- | |
| Cost of Revenue | 64.01% | 67.21% | 119.46% | 113.37% | |
| Gross Profit | -61.23% | -66.97% | -118.11% | -113.36% | |
| SG&A Expenses | 288.10% | 276.18% | 179.21% | 82.02% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 98.93% | 101.67% | 131.95% | 107.79% | |
| Operating Income | -96.58% | -101.49% | -131.14% | -107.78% | |
| Income Before Tax | -92.07% | -73.39% | -95.36% | -97.27% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -92.07% | -73.39% | -95.36% | -97.27% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -92.07% | -73.39% | -95.36% | -97.27% | |
| EBIT | -96.58% | -101.49% | -131.14% | -107.78% | |
| EBITDA | -96.63% | -101.40% | -131.19% | -107.83% | |
| EPS Basic | 89.43% | 92.39% | 88.81% | -36.03% | |
| Normalized Basic EPS | 85.64% | 88.68% | 84.00% | -45.12% | |
| EPS Diluted | 89.43% | 92.39% | 88.81% | -36.03% | |
| Normalized Diluted EPS | 85.64% | 88.68% | 84.00% | -45.12% | |
| Average Basic Shares Outstanding | 1,237.29% | 1,431.88% | 1,120.75% | 35.94% | |
| Average Diluted Shares Outstanding | 1,237.29% | 1,431.88% | 1,120.75% | 35.94% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
